Literature DB >> 30638795

Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.

Yalun Li1, Rui Zhang1, Yongzhao Zhou1, Juan Song1, Wenxin Luo1, Panwen Tian2, Weimin Li1.   

Abstract

Entities:  

Keywords:  Combination therapy; EGFR-TKIs; Leptomeningeal metastases; MET inhibitors; NSCLC

Mesh：

Substances：

Year:  2018        PMID： 30638795     DOI： 10.1016/j.cllc.2018.12.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

1.  High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

Authors:  A J Piper-Vallillo; Julia K Rotow; Jacqueline V Aredo; Khvaramze Shaverdashvili; Jia Luo; Jennifer W Carlisle; Hatim Husain; Alona Muzikansky; Rebecca S Heist; Deepa Rangachari; Suresh S Ramalingam; Heather A Wakelee; Helena A Yu; Lecia V Sequist; Joshua M Bauml; Joel W Neal; Zofia Piotrowska
Journal:  JTO Clin Res Rep       Date:  2022-04-21

2.  Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1/EphB3 pathway.

Authors:  Peng Sun; Limin Sun; Jia Cui; Lili Liu; Qing He
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.

Authors:  Miriam Blasi; Daniel Kazdal; Michael Thomas; Petros Christopoulos; Mark Kriegsmann; Regine Brandt; Anna-Lena Volckmar; Martina Kirchner; Claus Peter Heußel; Albrecht Stenzinger; Jonas Kuon
Journal:  Case Rep Oncol       Date:  2021-03-18

4.  Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways.

Authors:  Zhiqiang Wu; Bin Xu; Zhiyi Yu; Qin He; Zhuyuan Hu; Shishi Zhou; Meiqin Chen; Liang Zhu
Journal:  Biomed Res Int       Date:  2020-10-22       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.